行业研究 | 2026 年 FDA 多肽新药展望:6 款潜力产品引领行业破局

多肽圈
Feb 07

|中肽生化内容团队编辑尽管司美格鲁肽和替尔泊肽在过去一年几乎定义了全球多肽药物的商业高度,但如果把视角从“卖得多好”拉回到“批了多少新药”,2025 年对多肽而言,并不是一个令人兴奋的年份。相较于以往,多肽新药在监管端的产出明显偏少,甚至给人一种阶段性放缓的感觉。过去一年里,所谓的 “Tide” 军团中仅有四款新药获得 FDA 批准,而其中的主角并非多肽,而是寡核苷酸。多肽药物方面,唯一的新成员是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10